Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
BCTX BriaCell Therapeutics
5.700
-0.070-1.21%
Post Mkt Price
5.560
-0.140-2.46%
YOY
Do not show
Hide blank lines
(FY)2022/07/31(Q4)2022/07/31(Q3)2022/04/30(Q2)2022/01/31
Financial Ratios
Efficiency Ratios TTM
ROIC
-5,493.80% -79.818% -5,493.80% -79.818% -245.73% -46.771% -- -27.495%
ROE
-4,902.92% -79.416% -4,902.92% -79.416% -253.41% -46.320% -- -27.332%
ROA
-3,544.39% -53.347% -3,544.39% -53.347% -363.22% -40.918% 93.33% -24.576%
Efficiency Ratios
ROA 5 Year Average
9.90% -283.505% -- -- -- -- -- --
Profitability Ratios TTM
Financial Health Ratios
Total Assets to Common Equity
306.66% 412.212% 306.66% 412.212% -33.42% 101.407% -- 101.790%
Current Ratio
-56.65% 44.9976 -56.65% 44.9976 3.07% 126.2018 146,787.86% 79.8409
Quick Ratio
-57.58% 43.6365 -57.58% 43.6365 2.80% 121.6019 3,015,247.89% 79.3338
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- 0.000% -- -- -- -- -- --
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company, which engages in the development of immunotherapies for treatment of cancer. Its technologies include Bria-IMT and Bria-OTS. The company was founded by Charles L. Wiseman and Isaac B. Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.
CEO: Dr. William Williams, M.D.
Market: NASDAQ
Listing Date: 02/24/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist